Lilly rides Mounjaro, Zepbound to better
Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
Related articles
Hilarious moment mother asks her Cocker Spaniel to help choose her lottery numbers
This is the hilarious moment a woman enlisted the help of her Cocker Spaniel to help choose her lott2024-05-22Xi Meets Cambodian Prime Minister
Contact Us HomeNewsHighlightACWF NewsSocietyWom2024-05-22Automotive future lies in integrated technology: Research
Technology such as automation, connectivity or electrification alone can hardly push the automotive2024-05-22Luxury brands embrace the Year of the Dragon
As China prepares to celebrate the upcoming Chinese New Year - Year of the Dragon according to Chine2024-05-22- NEW YORK (AP) — Sabrina Ionescu scored 20 points and the New York Liberty beat the Seattle Storm 74-2024-05-22
- A lithium mine with nearly one million tons of reserves was newly discovered in Yajiang, Southwest C2024-05-22
atest comment